Evidence supporting the use of: Bifidobacteria (unspecified)
For the health condition: Crohn's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacteria (unspecified) have been investigated for their potential role in supporting or treating Crohn’s Disease, primarily due to their function as beneficial gut microbiota. Scientific interest has focused on the observed dysbiosis (microbial imbalance) in Crohn’s Disease patients, including reduced levels of Bifidobacteria. Several small-scale clinical trials and preclinical studies have evaluated probiotic supplementation—including Bifidobacteria species—as adjunct therapy. Some randomized controlled trials have tested multi-strain probiotic mixtures containing Bifidobacteria, with mixed or inconclusive results. For example, Bifidobacterium longum, in combination with other probiotics and prebiotics, has demonstrated some anti-inflammatory effects and modest improvements in symptoms in small cohorts, but results have not been consistently replicated, and studies are often limited by small sample size or methodological heterogeneity.

Meta-analyses and systematic reviews generally conclude that there is insufficient high-quality evidence to support the routine use of Bifidobacteria as a standalone treatment for Crohn’s Disease. Nonetheless, given the plausible mechanism (restoring gut microbial balance and modulating immune function), research continues. Currently, Bifidobacteria supplementation is not considered a standard or primary therapy for Crohn’s Disease, but may be used adjunctively in select cases. Overall, evidence is weak (rated 2/5), and further large, well-designed trials are needed to draw firm conclusions about efficacy.

More about Bifidobacteria (unspecified)
More about Crohn's Disease

Products containing Bifidobacteria (unspecified)

We currently have no products on Vitabase that contain this ingredient.